Intravitreal Anti-vascular Endothelial Growth Factor versus Observation in Acute Central Serous Chorioretinopathy: One-year Results

Park, Sang-Uk; Lee, Seungjun; Kim, Moo‐Sang

doi:10.3341/kjo.2014.28.4.306

Cited by 19 publications

(20 citation statements)

References 32 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[19][20][21] There is also emerging evidence that early resolution of SRF could reduce the risk of photoreceptor/ RPE degeneration and improve visual acuity. 22 However, in our study, despite the shorter resolution time in spontaneously resolved group, no difference was found between the groups in respect to the visual acuity changes during follow up. One possible reason for this nonsignificance may be the relative shorter recovery time in PDT-treated patients.…”

Section: Discussioncontrasting

confidence: 48%

The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case–control study

Özkaya

Alkın

Özveren

et al. 2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate the resolution time and the recurrence rate of acute central serous chorioretinopathy (CSC) after spontaneous resolution and low-fluence photodynamic therapy (PDT). Methods Case-control study: The CSC patients who were admitted to our clinic for the first time were included. No treatment was given during the first 6 months. Patients were treated with PDT after 6 months from the initial signs of the disease, if they did not show any sign of resolution. The patients who showed a significant decrease in subretinal fluid after month 6 were not scheduled for PDT. The primary outcomes were the resolution time and the recurrence rate after the first episode. Secondary outcome measures were the change in BCVA and CRT during the follow up. Results A total of 77 consecutive eyes of 77 patients were included, 41 eyes (53.2%) with spontaneously resolved CSC and 36 eyes (46.8%) with PDT-treated CSC. The initial resolution time was 4.1 ± 3.2 months in spontaneous resolution group, and 8.1 ± 0.8 months in PDT group, respectively (Po0.001). The recurrence rate was 51.2% in spontaneous resolution group, and 25% in PDT group (P = 0.01). The change in BCVA from baseline to the last follow-up visit was statistically significant in both groups (P = 0.002, P = 0.003, respectively). The change in CRT from baseline to the last follow up was also statistically significant in both groups (P = 0.002, P = 0.003, respectively). Conclusions The recurrence rate of acute CSC was lower in PDT-treated patients than the spontaneously resolved patients.

show abstract

Section: Discussioncontrasting

confidence: 48%

The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case–control study

Özkaya

Alkın

Özveren

et al. 2016

Eye

View full text Add to dashboard Cite

show abstract

“…The study comparing results of PDT treatment and sole 689 nm laser treatment of CSCR showed that both procedures were equally effective; however, it included cases of relatively short duration of CSCR (17-19 weeks) [ 25 ]. The efficacy of anti-VEGF treatment in chronic CSCR is disputable [ 26 – 29 ], with recent data failing to confirm its superiority over PDT or other therapies [ 30 , 31 ].…”

Section: Introductionmentioning

confidence: 99%

Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser

Gawęcki¹,

Jaszczuk-Maciejewska²,

Jurska-Jaśko³

et al. 2017

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

BackgroundChronic central serous chorioretinopathy is a serious therapeutic problem as it may lead to significant visual impairment. The aim of this retrospective study is to evaluate functional and morphological effects, as well as factors influencing visual outcome in patients treated by subthreshold micropulse laser.MethodsFifty-one eyes with chronic central serous chorioretinopathy lasting longer than 4 months (18 months on average) underwent up to two sessions of subtreshold micropulse laser treatment. Change in best corrected visual acuity, central retinal thickness, central retinal volume, average central retinal thickness and maximum subretinal fluid height were measured. Relation between the effects of the treatment and the initial retinal morphological and functional parameters was then analyzed.ResultsThe total resorption of subretinal fluid was achieved in 36 cases (70.6%). There was, however, only a minor improvement in best corrected visual acuity of approximately one line on the Snellen chart. No correlation was observed between the effects of the treatment and the duration of the symptoms, retinal morphology and initial visual acuity. Younger patients responded better to the therapy.ConclusionSubthreshold micropulse laser treatment in chronic serous chorioretinopathy provides good morphological results, however significant improvement of visual acuity is not to be expected.

show abstract

“…40 Therefore, these agents have a relatively minor and controversial role in the treatment of CSC. 1,41,42 Oral treatment for CSC is an appealing idea, if it can be proven to be effective and systemically safe. Such a treatment could be the first treatment choice for patients with CSC who require intervention, to which PDT could be added later on if necessary.…”

Section: Discussionmentioning

confidence: 99%

Finasteride is effective for the treatment of central serous chorioretinopathy

Moisseiev

Holmes

Moshiri

et al. 2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate the safety and efficacy of finasteride treatment in patients with central serous chorioretinopathy (CSC). Methods Retrospective review of 29 eyes of 23 patients who were treated with finasteride for CSC. Previous medical and ocular history, steroid use, length of finasteride treatment, additional treatments for CSC, visual acuity (VA), central macular thickness (CMT), and presence of subretinal fluid (SRF) throughout the follow-up period, and the occurrence of any complications were recorded. Results Initial VA was 0.29 ± 0.31 logMAR, and a trend towards improved VA was noted after 3 months (0.25 ± 0.36 logMAR; P = 0.07). VA was significantly improved at the final follow-up (0.23 ± 0.27 logMAR; P = 0.024). Initial CMT was 354 ± 160 μm, and was significantly reduced after 1 month of treatment (284 ± 77 μm; P = 0.002) and this was maintained to the end of follow-up (247 ± 85 μm; P = 0.001). A significant reduction in SRF presence was found at all time points, with an overall 75.9% rate of complete resolution. Following discontinuation, SRF recurrence was noted in 37.5% of cases. No adverse events were recorded. Conclusions Finasteride is a safe and effective treatment for CSC. It may be a possible new option for the initial management of patient with CSC, and a suggested treatment approach is presented.

show abstract

Intravitreal Anti-vascular Endothelial Growth Factor versus Observation in Acute Central Serous Chorioretinopathy: One-year Results

Cited by 19 publications

References 32 publications

The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case–control study

The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case–control study

Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser

Finasteride is effective for the treatment of central serous chorioretinopathy

Contact Info

Product

Resources

About